|
3M is submitting updated data and studies on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds to the EPA, including revised reports on the Tennessee River study and addenda correcting reported values in PFOS ecotoxicological studies due to new analyses of sample purity.
|
2004 |
AR226-1717
|
3NMerwOYo93Qd8BEMr4VRxxrJ |
8 |
|
This is a bibliography of published literature related to perfluorinated compounds, including studies on perfluorooctanoic acid and its environmental impacts.
|
2004 |
AR226-1718
|
E3xrKm7JQXKNEDEG3vVZY3Zx |
5 |
|
The document is a final report on a study evaluating the metabolism and toxicological effects of perfluorooctanesulfonamide (FOSA) in male rats, specifically focusing on hepatic peroxisome proliferation after administering a dose of 40 mg/kg/day for four consecutive days.
|
2004 |
AR226-1731
|
mp7Q2k5oJ85nyQ9OnObNxDv7k |
18 |
|
The document is a final report of a pharmacokinetic study conducted by 3M on perfluorooctanesulfonyl fluoride (POSF), which was found to be metabolized to perfluorooctanesulfonate (PFOS) in rats, with maximum liver levels of PFOS observed at approximately 11 ppm on day 4 post-dose.
|
2004 |
AR226-1695
|
0JgX22pjkB6X21yzDkgwzb7eb |
11 |
|
3M submitted a TSCA 8(e) supplemental report to the EPA indicating that an oral pharmacokinetic study in rats showed that perfluorooctanesulfonyl fluoride (POSF) metabolizes to perfluorooctane sulfonate (PFOS), with maximum PFOS levels in the liver observed at 11 ppm on day 4 post-dose.
|
2004 |
AR226-1781
|
GKRop6GvaONM9Z4LOV0wyJb0m |
1 |
|
3M submitted a supplemental report to the EPA regarding a pharmacokinetic study on ammonium perfluorooctanoate (PFOA) in rats, following previous communications about related reproductive studies.
|
2004 |
AR226-1550
|
NGx7p9Yo8yKEnZQp9dDB2pe98 |
1 |
|
3M submitted a supplemental report to the EPA detailing the results of a study on ammonium perfluorooctanoate (PFOA) that examines the age effect on plasma concentration in post-weaning rats following oral gavage.
|
2004 |
AR226-1552
|
o9aE40oaJ5D5Bea4b6Byky293 |
1 |
|
The document is an amended final report from 3M's Medical Department detailing a study on the metabolites of PFOS, specifically noting a change in the conclusion regarding FOSA as a metabolite of PFOS.
|
2004 |
AR226-3630
|
YD4M81M6J5pnk23dkq87r0EL8 |
4 |
|
A mortality study of perfluorooctanesulfonyl fluoride (POSF) manufacturing workers found a significant excess risk of bladder cancer associated with high levels of exposure to perfluorooctanesulfonate (PFOS), prompting further investigation through a questionnaire-based study to ascertain bladder cancer cases among the cohort.
|
2004 |
AR226-3630
|
LpQG98g6rEO4QKdwVyMdpwjq5 |
29 |
|
3M submitted a supplemental report to the EPA regarding a lactational and placental transport pharmacokinetic study in rats involving ammonium perfluorooctanoate (PFOA), following previous communications about related reproductive studies.
|
2004 |
AR226-1781
|
RwK63rQRNzkO876JjQxyzR78 |
1 |
|
DuPont submitted three abstracts related to perfluorinated compounds, authored by James Dahlgren for plaintiffs in a class action lawsuit, to the EPA for informational purposes, clarifying that the abstracts do not indicate any actual risk or meet reporting criteria under TSCA Section 8(e).
|
2004 |
AR226-1770
|
MG1OgX2QxpLd92vNxZNqzy44y |
4 |
|
DuPont submitted air monitoring data related to PFOA from its Washington Works facility to the EPA as part of an Air Modeling Verification Study, including preliminary results and analytical reports on particle size distribution.
|
2004 |
AR226-1774
|
ymdj5B05p9pVg0kXOoRXL0wm4 |
3 |
|
This document summarizes intermediate results from the Air Modeling Verification Study related to PFOA air monitoring at the DuPont Washington Works site, detailing initial comparisons between monitored ambient air measurements and air dispersion modeling results.
|
2004 |
AR226-1775
|
KzJ4rJ4mKj34d4a3oYmqK9YBX |
4 |
|
The document is a review of a toxicity study on perfluorooctanesulfonyl fluoride (POSF) conducted by 3M, indicating that while there are treatment-related effects observed in the liver, the urinary tract, including the kidneys and bladder, shows no significant abnormalities.
|
2004 |
AR226-3630
|
jm9DKGBpYaE3Qb9g6KEmqEEr2 |
2 |
|
The document is a final report from 3M's Corporate Toxicology department detailing an inter-species comparison study of the mechanisms of toxicity for perfluorooctanesulfonate (PFOS) and ammonium perfluorooctanoate (APFO) following intraperitoneal dosing in rats and guinea pigs, as well as oral dosing of N-ethyl perfluoroo
|
2004 |
AR226-3630
|
EvKK0KQ9JZEwJ1vnR8Yqxm5VL |
44 |
|
This document is a correspondence from Taft, Stettinius & Hollister LLP to the EPA regarding the PFOA Environmental Monitoring/Sampling Information, providing additional documents related to environmental modeling and sampling for PFOA conducted by DuPont at various facilities.
|
2004 |
AR226-1669
|
zQ4yJpqwaLoOR6x2nvp4pxkd0 |
2 |
|
This document is a correspondence from 3M to the EPA, providing additional background information and data regarding monitoring programs related to perfluorinated chemicals, specifically including a Carbon Adsorption Study for the removal of PFOA from wastewater.
|
2004 |
AR226-1781
|
ZBM9beEJL2EORG8edy0BJzjJY |
2 |
|
The document details the sample tracking of wildlife samples from Michigan State University that were analyzed for concentrations of perfluorinated compounds at 3M, including sample IDs and storage conditions.
|
2004 |
AR226-1781
|
ymaqz7rq14BjD5XknNnkKwnD4 |
8 |
|
3M submitted additional data and revised reports on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds to the EPA, including corrections to ecotoxicological studies based on new analyses of sample purity.
|
2004 |
AR226-1781
|
O1Vo56Z6GLnyaeQKOexVXr7me |
13 |
|
This document reports on a study evaluating the metabolism and toxicological effects of perfluorooctanesulfonamide (FOSA) in male rats, comparing its effects to other compounds, with a focus on hepatic peroxisome proliferation after administering a dose of 40 mg/kg/day for four consecutive days.
|
2004 |
AR226-1781
|
EdBQjM8EJ7qwY8vBD02O3egzj |
19 |
|
The document outlines the agenda for a meeting between DuPont, 3M, and the EPA on August 25, 2004, focusing on the review of worker exposure data and biological studies related to perfluorinated compounds.
|
2004 |
AR226-1838
|
3Ea8rzX4omzmYxL1jEg8X0L6 |
2 |
|
3M submitted a corrected version of final reports for reproductive avian toxicity studies on perfluorooctanesulfonate (PFOS) in northern bobwhite quail and mallard duck to the EPA, addressing issues of illegibility and omissions from a prior submission.
|
2004 |
AR226-1839
|
qm9522Q7jRG6Q3MmVBD6M2yjK |
3 |
|
The document is an index of TSCA Section 8(e) docket submissions by 3M Company, detailing various pilot, acute, and definitive studies on the toxicological effects of Potassium Perfluorooctanesulfonate (PFOS) on Northern Bobwhite Quail and Mallard Ducks, including methods for extraction and analysis using HPLC-Electrospray/Mass Spectrometry.
|
2004 |
AR226-1840
|
DGNwy4EpR7gN1Vjx0qeQL1eRQ |
2 |
|
3M reported to the EPA that preliminary data from an acute inhalation toxicity study on methyl perfluoroisobutyrate indicated neurotoxicity in rats exposed to 3000 ppm, while no adverse effects were observed at 300 ppm.
|
2004 |
AR226-1862
|
a1aBbX1j7DDjM48m8G5GeyrOa |
2 |
|
The document is an analytical report from Exygen Research detailing the analysis of perfluorooctanoic acid (PFOA) in human serum samples received from Dr. Marsha Bailey, indicating that twelve samples were analyzed using high-pressure liquid chromatography and mass spectrometry methods.
|
2004 |
AR226-1864
|
EvB48q7k4ByKmDwz5jam07mNx |
10 |
|
This document is a letter from Edward E. Shea representing MIC Specialty Chemicals, Inc., submitting a report regarding biological monitoring of workers exposed to perfluorooctanoic acid (PFOA) from Miteni S.p.A. to the EPA, indicating that the information appears favorable but is submitted as a precautionary measure.
|
2004 |
AR226-1865
|
rx9161YyXpEYKXk3NKK40y9Eq |
1 |
|
The document reports on a meeting held in August 2004 between representatives from 3M, DuPont, and Miteni to discuss the analysis of data collected on workers exposed to PFOA at the Miteni plant, emphasizing the importance of this data for understanding PFOA's interaction with human physiology.
|
2004 |
AR226-1866
|
da196pkRnRBLQDzvprExjgrq0 |
8 |
|
This document is a letter submitted to the EPA by DuPont regarding a meeting about the health effects of Ammonium Perfluorooctanoate (PFOA) on workers at the Miteni plant, noting no significant health effects but higher serum levels of PFOA compared to general population levels, and indicating a need for further analysis of observed lipid level changes.
|
2004 |
AR226-1867
|
e5bj7GBw0QxebOeOo5YJBeVky |
2 |
|
This document reports the results of an oral repeated dose toxicity study conducted by DuPont on PFOA in rats and mice, indicating that all test materials (linear, branched, and a mixture) caused similar biological responses, including increased liver weights and changes in lipid chemistry, with mortality observed in one mouse at the highest dose of the linear form.
|
2004 |
AR226-1872
|
y2MZ0GBBOYwreXZ3orne8MMn |
1 |
|
The document is a submission to the EPA under TSCA Section 8(e) by a company providing worker monitoring data on blood levels of perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorodecanoic acid (PFDA) from 281 workers at their facility, while arguing that the data does not constitute "
|
2004 |
AR226-1873
|
npqJ6529yeQ7bqda724oE95mz |
5 |
|
This document is a supplemental submission to the EPA regarding a toxicology study conducted by 3M on dermal contact absorption of PFOS (perfluorooctanesulfonate) and other perfluorinated compounds in rats, indicating that these compounds were found in liver and serum samples after exposure to certain carpet and upholstery protector products that 3M has phased out.
|
2004 |
AR226-1874
|
peG39Q9DkqVJyw1KmDYQ15o2B |
1 |
|
The document is a correspondence from DuPont Fluoroproducts regarding monitoring data related to PFOA, submitted in compliance with the PFOA Users Letter of Intent, indicating ongoing compliance efforts and data reporting.
|
2004 |
AR226-1875
|
a4K9p4yMxbVRv7b92yJ7zypJe |
1 |
|
The document outlines monitoring and reduction efforts for PFOA by Daikin America in Decatur, AL, detailing wastewater and sludge monitoring results, with a focus on identifying sources and implementing measures to reduce PFOA releases into the environment.
|
2004 |
AR226-1878
|
wDZzxGLNqoZbRo6XbxXaBjnko |
24 |
|
The document is a letter from the Haskell Laboratory for Health and Environmental Sciences to the EPA's Office of Pollution Prevention and Toxics, expressing appreciation for a meeting to review DuPont's work related to PFOA and telomers.
|
2004 |
AR226-1879
|
0Yzzd82K02eeeOZM6kboYGmO |
1 |
|
The document summarizes various toxicological studies conducted by 3M on perfluorinated compounds, specifically focusing on PFOS and N-EtFOSE, examining their mechanisms of toxicity in rats and guinea pigs through different dosing methods.
|
2004 |
AR226-3630
|
99p0xnjrj11NoB7r8EgaYVqN5 |
1 |
|
The document includes attachments related to 3M's fluorochemical submission, specifically detailing an analytical report on human serum for fluorochemicals and a final report on the effects of perfluorobutanesulfonate, perfluorohexanesulfonate, and perfluorooctanesulfonate on cholesterol metabolism.
|
2004 |
AR226-3630
|
3eXEaV180vqmmNd8p0LzLKbbn |
1 |
|
The document is a submission by 3M detailing a study by Butenhoff et al. on the characterization of risk for general population exposure to perfluorooctanoate (PFOA), published in Regulatory Toxicology and Pharmacology in April 2004.
|
2004 |
AR226-3630
|
B8j0zqnd1qmJ2YRQ9LMEnak2E |
1 |
|
The document discusses a study by Bruce H. Alexander from the University of Minnesota on bladder cancer in workers manufacturing perfluorooctanesulfonyl fluoride (POSF), submitted by 3M in November 2004.
|
2004 |
AR226-3630
|
mqJvd7Q3LL7jDKr72794YJoXZ |
1 |
|
The document is a submission by 3M detailing a study by Butenhoff et al. on the characterization of risk for general population exposure to perfluorooctanoate (PFOA), published in Regulatory Toxicology and Pharmacology in April 2004.
|
2004 |
AR226-3630
|
O3Q36R9QGYdjpw724GDyK5RxM |
1 |
|
The document is a submission from 3M regarding a study by DuPont on the effects of age on plasma concentrations of PFOA in post-weaning rats following oral gavage.
|
2004 |
AR226-3630
|
RaZyMXZap4KbnQ9RebpBOob1z |
1 |
|
This document is an amendment to a final report by 3M regarding a molecular biology study on the comparative effects of various perfluorinated compounds, including PFOS, N-EtFOSE, N-EtFOSA, FOSAA, and FOSA, on rats and guinea pigs following oral dosing.
|
2004 |
AR226-3630
|
kDVBgO1kR63EGm9Vkzwwxnvx0 |
1 |
|
This document includes a review letter by Samuel M. Cohen regarding a 90-day inhalation toxicity study on PFOS, dated June 18, 2004, and a peer review of a two-year oral toxicity-oncogenicity study in rats conducted by Experimental Pathology Laboratories and DuPont, dated June 25, 2004.
|
2004 |
AR226-3630
|
ypev5BjRmrpYzwavJ4n5j606r |
1 |
|
The document details two studies conducted by 3M's Medical Department on the toxicity mechanisms of perfluorooctanesulfonate (PFOS) and other perfluorinated compounds in rats and guinea pigs, focusing on inter-species comparisons and molecular biology findings.
|
2004 |
AR226-3630
|
Y97dV4yvzrJyym9qDwo3y1yO |
1 |
|
Empty document.
|
2004 |
AR226-3630
|
Ozwb36bpoB2YbN3bnV77NOEEM |
1 |
|
The document outlines various toxicological studies conducted by 3M on perfluorinated compounds, specifically focusing on PFOS and N-EtFOSE, including inter-species comparisons and cell proliferation studies in rats and guinea pigs.
|
2004 |
AR226-3630
|
O1QRdyKQD6e97r0RML9jdEQxj |
1 |
|
The document presents an overview of DuPont's research and publications related to Ammonium Perfluorooctanoate (APFO) and telomers, including studies on toxicology, human biomonitoring, and environmental effects, as presented to the US EPA by Robert W. Rickard, Ph.D.
|
2004 |
AR226-1880
|
Eq0zzeVeQYq2G5JxVo2JagODR |
56 |
|
The document is a submission from DuPont's legal counsel to the EPA, reporting that an analytical study by the West Virginia Department of Environmental Protection found no detectable levels of perfluorooctanoic acid (PFOA) in fish samples collected near the Belleville Lock and Dam.
|
2004 |
AR226-1882
|
gDB2mz6aNpN4yGoy7qeoVBR5Q |
2 |
|
The document is a correspondence from DuPont's Haskell Laboratory discussing ongoing research related to perfluorinated compounds, specifically mentioning the analysis of samples for PFOA and indicating that a report on the findings will be submitted.
|
2004 |
AR226-1884
|
MJZkR5xZbO1RVXLgBLnLQea4j |
1 |
|
The document is an analytical report from Exygen Research detailing the analysis of perfluorooctanoic acid (PFOA) in fish samples collected by the West Virginia Department of Environmental Protection, indicating the methodology and preparation for testing the samples.
|
2004 |
AR226-1883
|
dYyDXwZ03j2Kgd9rRExwdmwLb |
52 |
|
The document is a submission from the Telomer Research Program, including companies like DuPont and Daikin, to the EPA, providing an updated guidance document on best analytical practices for studies related to perfluorinated compounds.
|
2004 |
AR226-1887
|
oDe8gMOv2rEko20Qzw2jwyagE |
1 |
|
The document provides guidance on best analytical practices for studies related to non-volatile fluorinated compounds, emphasizing the importance of method validation and contamination prevention in the Telomer Research Program sponsored by companies including Asahi Glass Co., Ltd. and DuPont Chemical Solutions Enterprise.
|
2004 |
AR226-1888
|
0v79mRgx8kkjrdgLVrRLxXZR |
8 |
|
The document is a submission from the Telomer Research Program, representing companies including DuPont and Daikin Industries, to the EPA, providing a study report on "(14C)-8-2 Telomer B Alcohol: Adsorption/Desorption using a Batch Equilibrium Method" for inclusion in the administrative record.
|
2004 |
AR226-1889
|
EBR09X3knndyrJdYvQnmV8pb |
1 |
|
The document reports on a study conducted by Covance Laboratories to determine the adsorption/desorption characteristics of (14C)-8-2 Telomer B Alcohol (2-perfluorooctylethanol) in various soil types and sediment, following OECD Guideline 106.
|
2004 |
AR226-1890
|
9RVbvovmw3ap3nm2XN3mYRq6 |
8 |
|
The document outlines the agenda and purpose of a technical meeting held by the EPA and DuPont on December 15, 2004, to discuss degradation studies of telomer substances, which are related to perfluorinated compounds.
|
2004 |
AR226-1892
|
Dv79q11Nrv1GKYrNvvj88amEB |
81 |
|
The document presents findings from a health study on reproductive effects and cancer rates in residents exposed to PFOA from a large C8 source, indicating increased PFOA levels correlate with lower testosterone and higher estrogen in male workers, and significantly elevated rates of uterine/cervical cancer among residents compared to expected rates.
|
2004 |
AR226-1894
|
50LOKeZBbBdBxgjajrY12mo2V |
10 |
|
The document reports on a toxicokinetic study conducted by 3M to assess the absorption and metabolism of FC methyl carboxamide (T-7483.1) in rats, specifically measuring the excretion of perfluoroctanoate (PFOA) in urine following oral administration.
|
2004 |
AR226-1896
|
aOL2RxDrr95MEkqGOmkxyqra |
13 |
|
The document details various toxicological studies conducted by 3M on perfluorinated compounds, specifically PFOS and N-EtFOSE, including inter-species comparisons and molecular biology studies in rats and guinea pigs.
|
2004 |
AR226-1901
|
YDayBKMY3VGx2MRk9K9vGLybD |
2 |
|
The document is a final report on a low-level oral toxicokinetic study of perfluorooctanesulfonate (PFOS) conducted by 3M's Medical Department, detailing the serum and liver concentrations of PFOS in rats.
|
2004 |
AR226-1898
|
xdkgErB1bkZ3VnBRqVYGRvp8y |
158 |
|
The document is a final report from 3M's Corporate Toxicology department detailing an inter-species comparison study of the toxicity mechanisms of perfluorooctanesulfonate (PFOS) and ammonium perfluorooctanoate (APFO) in rats and guinea pigs, as well as N-ethyl perfluorooctanesulfonamido ethanol (N-E
|
2004 |
AR226-1902
|
xjDnpgvd29a25B27KkqoZLx9E |
44 |
|
The document is an amended final report from 3M detailing a comparative molecular biology study on various perfluorinated compounds, including PFOS and its metabolite FOSA, conducted on rats and guinea pigs, with a specific focus on clarifying the conclusions regarding FOSA as a metabolite of PFOS.
|
2004 |
AR226-1904
|
QJoL7k2rjeOj4LvQMNB7bvjB4 |
4 |
|
The document outlines a two-year oral toxicity and oncogenicity study of PFOA conducted on rats by DuPont, detailing the methodology and findings related to the compound's effects.
|
2004 |
AR226-3630
|
nk1jgJb99ZrVGZOV6kBRavrg1 |
15 |
|
The document characterizes the risk of general population exposure to perfluorooctanoate (PFOA), reporting that serum concentrations in the U.S. population are significantly lower than levels associated with adverse effects in toxicological studies, resulting in margins of exposure (MOE) ranging from 1600 to 8900.
|
2004 |
AR226-3630
|
reRvjmydRk9QzRyjjErdXDKmV |
18 |
|
The document details a study conducted by E.I. du Pont de Nemours and Company on the effects of age on plasma concentrations of ammonium perfluorooctanoate (PFOA) in post-weaning rats following oral gavage, completed on December 2, 2004, and compliant with Good Laboratory Practice standards.
|
2004 |
AR226-3630
|
d7Z8ZkvbdZGpRow8vOYd68J9 |
52 |
|
The document is a final report from 3M's Medical Department detailing a comparative molecular biology study on various perfluorinated compounds, including PFOS, conducted on rats and guinea pigs following oral dosing, with the study directed by Andrew M. Seacat.
|
2004 |
AR226-3630
|
b5z6mQzJzX1dL6J7ZyYB19Ybg |
209 |
|
A mortality study of workers at a perfluorooctanesulfonyl fluoride (POSF) manufacturing facility found a significant excess risk of bladder cancer associated with high exposure to perfluorooctanesulfonate (PFOS), prompting further investigation through a questionnaire and medical record validation.
|
2004 |
AR226-1908
|
3NoJBz0N4VBx06anm4x1JoGVy |
29 |
|
The document is a final report from 3M Medical Department detailing a comparative molecular biology study on various perfluorinated compounds, including PFOS, conducted on rats and guinea pigs following oral dosing, with study numbers T-6295.8, T-6316.4, T-6868.2, T-7071.1, and T-7132.1.
|
2004 |
AR226-1903
|
nmMRBqQQVO7DvZ62mgRJ3Za38 |
211 |
|
The document reports on a study conducted by E.I. du Pont de Nemours and Company examining the age effect on plasma concentrations of ammonium perfluorooctanoate (PFOA) in post-weaning rats following oral gavage.
|
2004 |
AR226-1909
|
aDV5JJ5jEBqRVzNgDYbmYJJ4B |
52 |
|
The document is a peer-reviewed study by Peter C. Mann on the two-year oral toxicity and oncogenicity of FC-143 (a perfluorinated compound) in rats, focusing on ovarian effects.
|
2004 |
AR226-1921
|
e7VLbXVXRMY27EjQLRnBZMMnm |
15 |
|
The document is a submission of a study report on "8-2 Telomer B Alcohol: Developmental Toxicity Study in Rats" by the Telomer Research Program, which includes member companies such as DuPont, to the EPA for inclusion in the administrative record.
|
2004 |
AR226-1938
|
p2B5Vykk7ydGaRzx6pG8GQ2bj |
1 |
|
A mortality study of workers at a perfluorooctanesulfonyl fluoride (POSF) manufacturing facility found a significant excess risk of bladder cancer associated with high exposure to perfluorooctanesulfonate (PFOS), prompting further investigation through a questionnaire and medical record validation among the cohort.
|
2004 |
AR226-1954
|
1g3yMzzdOMwYD9rrqqO1mDn4q |
29 |
|
The document is an analytical report from AXYS Analytical Services detailing the detection of various perfluorinated compounds, including PFOA, in a water sample collected on November 22, 2004, with specific concentration values and detection limits provided.
|
2004 |
AR226-1959
|
NZ5OV5Oe6Og9pNEZVwEV7MQ8 |
10 |
|
The analysis report from AXYS Analytical Services indicates that PFOA was found at a concentration of 1.61 ng/g and PFOS at 5.60 ng/g in solid samples collected on November 24, 2004.
|
2004 |
AR226-1961
|
Dd0yxp96M9K4JR4NBzJO2483N |
29 |
|
This document communicates a change in the C-8 (perfluorooctanoic acid, PFOA) air monitoring program for TEFLON personnel, indicating a reduction in personal and area sampling frequency based on high levels of previous monitoring, while initiating a characterization study of job classifications with C-8 exposure to determine necessary sampling.
|
2004 |
AR226-2004
|
yrjJrM6Yxo2j1Q7Br0pbrEnyD |
1 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding a fluorochemical salt, indicating that an acute oral toxicity study in rats revealed potential neurotoxic effects, with an established oral LD50 of 200-2000 mg/kg, as the company investigates its use as a surfactant in semiconductor processing.
|
2004 |
AR226-1778
|
ybmdYL5OG3rZRVqb1DrJRLMEn |
2 |
|
3M submitted a compact disc (CD No. 6) to the EPA containing studies on perfluorooctane sulfonates and related compounds, continuing their voluntary data sharing and dialogue regarding fluorochemicals.
|
2004 |
AR226-1780
|
4aryONBErGQ22Dqdy60rZdQeG |
1 |
|
This is a study report from NOTOX B.V. assessing the acute oral toxicity of T-7868 in rats, completed on April 20, 2004, under project identification NOTOX Project 389598.
|
2004 |
AR226-1779
|
QJ0pE28njGeRnwR6jrZ6Ev55E |
15 |
|
This correspondence from Taft, Stettinius & Hollister LLP to the EPA discusses the PFOA ECA process and includes documents obtained from DuPont related to PFOA degradation studies, while noting that some documents are confidential and cannot be shared.
|
2004 |
AR226-1782
|
XOxpo5GMMEZ0O0evODK9o7xxJ |
3 |
|
3M submitted a TSCA 8(e) supplemental report indicating that a 90-day inhalation study in rats showed perfluorooctanesulfonyl fluoride (POSF) metabolizes to perfluorooctane sulfonate (PFOS), while perfluorooctanoate (PFOA) was detected as a manufacturing residual but not as a metabolite of
|
2004 |
AR226-1800
|
aBp9On76MgR6dq4X4k9bDd9aa |
2 |
|
This is a letter from Asahi Glass Co., Ltd. dated July 9, 2004, addressing Mr. Lynch regarding the GPC chromatographic analysis results.
|
2004 |
AR226-1801
|
4JX1bE9LqgBR7aj8B969Oe05a |
2 |
|
Asahi Glass Co., Ltd. conducted a characterization study of a polymeric product (AAA) which included measurements of total organic fluorine and PFOA content, using various analytical methods to assess its composition.
|
2004 |
AR226-1802
|
YjJ0n0dK2L848kBMOnMKo4ajD |
20 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding a protective material after a four-hour acute inhalation study in rats revealed significant respiratory issues and fatalities, despite an exposure assessment indicating minimal risk when the product is used as directed.
|
2004 |
AR226-1804
|
yOm3L2L3JLV3EmNL61R9pvM2 |
3 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding a protective material, detailing a four-hour acute inhalation toxicity study in rats that resulted in breathing abnormalities, body weight loss, and the death of four animals after exposure to the test substance vapor.
|
2004 |
AR226-1805
|
n9ooY3qE9v7D3x4p1e4oYpgL6 |
5 |
|
This document is a submission of groundwater and wastewater monitoring data related to perfluorooctanoic acid (PFOA) from 3M's manufacturing sites in Cottage Grove, MN, and Decatur, AL, as required by the Letters of Intent (LOIs) dated March 2003, highlighting ongoing monitoring efforts following the phase-out of PFOA production.
|
2004 |
AR226-1808
|
omYw0gkRGDMowDM3Nmow9xYbg |
9 |
|
The document provides an estimate of the quantities of Aqueous Film Forming Foam (AFFF) in the United States, highlighting the phaseout of PFOS-containing AFFF by 3M and the distinction between ECF-based and telomer-based AFFFs, as commissioned by the Fire Fighting Foam Coalition.
|
2004 |
AR226-1807
|
w9EdxpOaKxdYMXgGvZeVK5zV |
45 |
|
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA regarding studies on the metabolism of perfluorooctane sulfonyl fluoride (POSF)-based compounds, noting that perfluorooctanesulfonate (PFOS) is the ultimate degradation product of these compounds, which 3M phased out of commercial production in 2002.
|
2004 |
AR226-1809
|
yrv7zQDOrYjM80LmOn2JjD5aX |
3 |
|
The document is an amended final report from 3M's Corporate Toxicology department detailing a study on the comparative molecular biology of various perfluorinated compounds, including PFOS, and their metabolites in rats and guinea pigs, with a specific amendment to the conclusion regarding FOSA as a metabolite of PFOS.
|
2004 |
AR226-1813
|
9LQoB6Y0Ybap7mOm8GbML93d7 |
4 |
|
The document is a final report from 3M's Medical Department detailing a comparative molecular biology study of various perfluorinated compounds, including PFOS, conducted on rats and guinea pigs following oral dosing.
|
2004 |
AR226-1811
|
RjzgMgzz92KbO5Bkbxbp069Ra |
74 |
|
3M submitted final reports on reproductive avian toxicity studies for perfluorooctanesulfonate (PFOS) in northern bobwhite quail and mallard ducks, indicating that PFOS may have accelerated post-reproductive phase regression effects compared to untreated birds, along with analytical reports and toxicological summaries.
|
2004 |
AR226-1815
|
JNrmqRZ6y36noagq6V1gxne2r |
1 |
|
The document is an index of TSCA Section 8(e) docket submissions by 3M Company detailing various toxicological studies and analytical reports on potassium perfluorooctanesulfonate (PFOS) involving Northern Bobwhite quail and Mallard ducks.
|
2004 |
AR226-1816
|
Qg5ObYv0OkLk5r3q1NrGGMzp8 |
2 |
|
The document is a final report from 3M's Corporate Toxicology department detailing an inter-species comparison study of the toxicity mechanisms of perfluorooctanesulfonate (PFOS) and ammonium perfluorooctanoate (APFO) in rats and guinea pigs, conducted between 1997 and 1998.
|
2004 |
AR226-1814
|
kDLmwwod8EpQv4BKaDRe2erKE |
45 |
|
DuPont is submitting additional information to the EPA in response to a November 4, 2004 request regarding perfluorinated compounds, indicating that they do not believe this information triggers reporting obligations under TSCA section 8(e).
|
2004 |
AR226-2742
|
YGEmM1wgZzgxGjxoJgDNm7XKn |
4 |
|
The document outlines a monitoring proposal for fluoropolymer manufacturing sites, specifically focusing on PFOA and PFOS monitoring at 3M and Dyneon in Decatur, AL, and DuPont in Parkersburg, WV, recommending a tiered approach to data collection and decision-making.
|
2004 |
AR226-2352
|
Gz6168GNvLV0Xba8nvpoqjnpx |
23 |
|
The document details the monitoring of PFOA emissions from Daikin America's Decatur Plant, reporting a total emission of 397 pounds over a year and outlining air dispersion modeling, surface water and sludge monitoring, and groundwater/soil sampling results.
|
2004 |
AR226-2353
|
vmgND4EJBngJzpeM27GR5ZOw |
11 |
|
The document outlines DuPont's 2004 multi-media sampling plan for PFOA and PFOS in West Virginia and Ohio, detailing air, water, soil, and biota sampling methods and objectives to compare ambient air concentrations with air dispersion modeling results.
|
2004 |
AR226-2354
|
9VGNQkZRKpXRrqN3veQELXRV |
29 |
|
The document discusses comments and questions regarding a draft soil and biota sampling procedure related to fluoropolymer investigations, emphasizing the need for clarity on sampling timing, definitions, and the inclusion of wind direction in relation to PFOA and PFOS deposition.
|
2004 |
AR226-2356
|
0q8Xneq2y0Ga62Ej50O0gMmem |
2 |
|
The document discusses proposed monitoring locations for sampling air, soil, and groundwater in Ohio related to PFOA (C-8) detected in private water sources, with recommendations for shifting sampling sites to better capture higher concentrations.
|
2004 |
AR226-2357
|
jyD2LjDO8MbkZjvXyNY9J2g5Z |
2 |
|
E.I. du Pont de Nemours and Company submitted a proposal to the West Virginia Department of Environmental Protection to address recommendations from the August 2003 "Final GIST Report" regarding the investigation of ammonium perfluorooctanoate (PFOA) in groundwater, with plans for further implementation upon approval.
|
2004 |
AR226-2360
|
bB6594NnL2GZGv43wzZmDeYpZ |
7 |
|
The document is a draft Phase II Monitoring/Sampling Work Plan for the DuPont Washington Works site in West Virginia, detailing air and water monitoring activities related to perfluorinated compounds, including sampling methods and analytical approaches.
|
2004 |
AR226-2358
|
xzO9qMda9wE9K2k7Dm2eqmo8g |
44 |
|
The document is a draft Phase II Quality Assurance Project Plan for the DuPont Washington Works site in West Virginia, outlining project management, organization, and quality objectives related to the assessment of perfluorinated compounds, including PFOA and PFOS.
|
2004 |
AR226-2359
|
3JReepy7qvJg4YB5Z3rzeM2M3 |
83 |
|
DuPont reported on the 3Q04 residential water sampling results for PFOA in Ohio and West Virginia, indicating that 17 water sources were sampled, with ongoing efforts to obtain permissions for additional residences as required by a Consent Order.
|
2004 |
AR226-2524
|
0qmGObDp3BkmzD94e7736wvbV |
6 |